跳至主要内容
临床试验/NL-OMON50327
NL-OMON50327已完成不适用

Double blind placebo controlled randomized intervention study to validate the beneficial effect of hydrocortisone on dexamethasone-induced neurobehavioral side effects in pediatric acute lymphoblastic leukemia - DexaDays-2 study

niversitair Medisch Centrum Utrecht0 个研究点目标入组 106 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
106

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • - Written informed consent
  • - Age 3-18
  • - Histologically or cytologically confirmed acute lymphoblastic leukemia (ALL)
  • - Inclusion in DCOG ALL medium risk group protocol
  • - Able to comply with scheduled follow-up

排除标准

  • - Patient or parent refusal
  • - Anticipated compliance problems
  • - Underlying conditions which affect the absorption of oral medication
  • - Pregnant or lactating patients
  • - Current uncontrolled infection or any other complication which may interfere
  • dexamethasone treatment
  • - Language barrier
  • - Pre-existing mental retardation
  • - Current oral hydrocortisone treatment
  • - Current risperidone treatment

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验